Frenkel A, Rosenthal J, Nezu A, Winston A
Department of Psychiatry, Beth Israel Medical Center, New York, NY 10003.
Mt Sinai J Med. 1990 Nov;57(6):348-52.
Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker. The patients were evaluated every four weeks for obsessive-compulsive symptomatology, anxiety, and depression. Significant improvement of obsessive-compulsive and anxiety measures were observed after four weeks, with maximal improvement at eight weeks. Depressed and nondepressed patients showed similar rates of improvement in obsessive-compulsive symptomatology. Overall, fluoxetine was tolerated well by all patients, and no serious side effects were observed. This study suggests that fluoxetine is an effective and safe treatment for obsessive-compulsive disorder, both for short-term alleviation and for long-term maintenance.
十名符合《精神疾病诊断与统计手册》第三版修订本（DSM-III-R）强迫症标准的门诊患者完成了一项为期32周的氟西汀开放标签研究，氟西汀是一种选择性5-羟色胺再摄取阻滞剂。每四周对患者的强迫症状、焦虑和抑郁情况进行评估。四周后观察到强迫和焦虑指标有显著改善，八周时改善最大。抑郁和非抑郁患者在强迫症状方面的改善率相似。总体而言，所有患者对氟西汀耐受性良好，未观察到严重副作用。这项研究表明，氟西汀对强迫症是一种有效且安全的治疗方法，无论是短期缓解还是长期维持。
